ShareThis Page
Company gets $20M in venture capital |

Company gets $20M in venture capital

| Saturday, February 18, 2006 12:00 a.m

A local company that has developed a test to help oncologists select the proper chemotherapy to treat cancer said Friday that it has completed a deal giving it $20 million in venture-capital funding.

Precision Therapeutics Inc. has developed a test that quantifies a patient’s likely response to single or multiple chemotherapy treatments.

“We plan on beginning the commercialization of this product to assist with ovarian and breast-cancer treatment,” said Chief Executive Officer Sean McDonald. “The funds will be used to extend and continue ongoing clinical trials and for further product development.”

The market for assisting physicians in determining which drugs, dosages and timeframes will best work is — in a word — huge.

“Unfortunately, there are 9 1/2 million people today living with cancer, with 1.3 million new cases diagnosed each year,” McDonald said. “Right now, there are more than 400 new cancer drugs in human trials, and 80 drugs that now are being used. A course (of treatment) can run between $40,000 and $80,000. A product or products that can help a physician determine how best to deliver treatment is extremely valuable.”

Precision Therapeutics is the second Pittsburgh company that McDonald has shepherded to success. About 16 years ago, he founded Automated Healthcare, based on his idea to place bar codes on medications and to use a robot to retrieve coded medicines.

McDonald sold his company to drug-distribution giant McKesson in 1996 for $65 million. He stayed for five years to continue running the company. Today, the company is known as McKesson Automation.

Five venture-capital firms took part in Precision Therapeutics’ funding, including three from Pittsburgh: Birchmere Ventures, Adams Capital Management and Draper Triangle Ventures.

Other investors are Techno Ventures Management of Boston, and Quaker BioVentures of Philadelphia. All but Quaker BioVentures are previous Precision Therapeutics’ investors.

Categories: News
TribLIVE commenting policy

You are solely responsible for your comments and by using you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.